A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatment

Part A: The proportion of subjects achieving a ≥35% spleen volume reduction from Baseline to Week 24, as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scan., Part B: The proportion of subjects in each arm achieving SVR of ≥ 35% at Week 24 by MRI/CT scan (central review)

Part A: Proportion of subjects with a reduction in total symptom score, Part A: To determine the duration of reduction of spleen volume, Part A: To determine the need for red blood cell (RBC) transfusion, Part A: The proportion of subjects who have RBC transfusion independence at week 24, Part A: To determine complete and partial remission of treated subjects, Part A: To determine time to death from any cause in treated subjects, Part A: To determine the pharmacokinetic/pharmacodynamic (PK/PD) profile of KRT-232, Part B: The proportion of subjects with reduction from Baseline to Week 24 in the total symptom score, Part B: Time from randomization to death from any cause, Part B: Progression free survival (PFS): time from randomization to either first occurrence of disease progression or death due to any cause, Part B: The proportion of subjects in each arm achieving spleen volume reduction, Part B: Time from initial spleen volume reduction until the first occurrence of disease progression, Part B: The proportion of subjects who have red blood cell transfusion independence at week 24

No related papers found yet.

Bulgaria, Croatia, Czechia, France, Germany, Greece, Hungary, Italy, Lithuania, Poland, Portugal, Romania, Spain